Pacific Biosciences of California Inc (NASDAQ:PACB)’s traded shares stood at 17.71 million during the last session, with the company’s beta value hitting 1.95. At the close of trading, the stock’s price was $2.08, to imply an increase of 13.66% or $0.25 in intraday trading. The PACB share’s 52-week high remains $10.65, putting it -412.02% down since that peak but still an impressive 44.23% since price per share fell to its 52-week low of $1.16. The company has a valuation of $569.64M, with an average of 8.45 million shares in intraday trading volume over the past 10 days and average of 9.64 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Pacific Biosciences of California Inc (PACB), translating to a mean rating of 2.19. Of 11 analyst(s) looking at the stock, 1 analyst(s) give PACB a Sell rating. 0 of those analysts rate the stock as Overweight while 4 advise Hold as 6 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
After registering a 13.66% upside in the last session, Pacific Biosciences of California Inc (PACB) has traded red over the past five days. The 5-day price performance for the stock is 17.51%, and -17.13% over 30 days. With these gigs, the year-to-date price performance is -78.80%. Short interest in Pacific Biosciences of California Inc (NASDAQ:PACB) saw shorts transact 52.14 million shares and set a 4.85 days time to cover.
The extremes give us $2 and $4 for target low and target high price respectively. As such, PACB has been trading -92.31% off suggested target high and 3.85% from its likely low.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
Looking at statistics comparing Pacific Biosciences of California Inc share performance against respective industry, we note that the company has outperformed competitors. Pacific Biosciences of California Inc (PACB) shares are 1.96% up over the last 6 months, with its year-to-date growth rate higher than industry average at 18.02% against 15.30%.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -9.76% for the past 5-year period. While 2024 is set for a -12.49% return in earnings, projections for the next 5 years are at -1.00% annually.
PACB Dividends
Pacific Biosciences of California Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Pacific Biosciences of California Inc (NASDAQ:PACB)’s Major holders
Pacific Biosciences of California Inc insiders hold 9.32% of total outstanding shares, with institutional holders owning 83.11% of the shares at 91.65% float percentage. In total, 83.11% institutions holds shares in the company, led by ARK INVESTMENT MANAGEMENT LLC. As of 2024-06-30, the company held over 33.21 million shares (or 12.3202% of shares), all amounting to roughly $45.5 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 26.0 million shares, or about 9.6443% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $35.62 million.
